14 sep: Salg af de danske vindaktiviteter
14 sep: Victoria Properties A/S – fortegningsemission, optagelse til hand..
14-09-2017 13:15:00

Successful Phase III trial for ALK’s tree allergy SLIT-tablet

Relateret indhold
14 sep - 
ALK-Abelló/Kempen: Reducerer til "sælg" og fastholder k..
14 sep - 
ALK-Abelló: Amerikanere reducerer sats på kursfald
13 sep - 
Torsdagens aktier: Japansk udfald mod Ambu trak aktien ..
Relateret debat
22 aug - 
Der hvor jeg tror man undervurderer potentialet er hast..
22 aug - 
Den har ihvertfald lavet et GC d. 08.06.2018, og både k..
22 aug - 
Alk brager nu igennem 1200. Men hvor langt skal den op ..

Copenhagen, 2017-09-14 13:15 CEST (GLOBE NEWSWIRE) --

 

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced the successful outcome of a pivotal Phase III clinical trial of its tree allergy sublingual immunotherapy (SLIT) tablet, with the trial meeting its primary efficacy endpoint. The tree SLIT-tablet is important to ALK's efforts to develop a full tablet portfolio for people suffering from the most common respiratory allergies. ALK is currently the only company that has completed Phase III clinical development with a tree SLIT-tablet. 

The primary endpoint of the trial was the daily total combined score, which is the sum of the allergic symptom score and the use of symptom-relieving medication, measured during the birch pollen season. Treatment with the tree SLIT-tablet reduced the total combined score (primary endpoint) by 39.6% compared to placebo. The results were highly statistically significant (p < 0.0001). The efficacy was similar when analysing data for the entire tree pollen season (i.e. including the alder and hazel pollen seasons). The trial also showed that the treatment was well-tolerated by patients, with no new or unexpected adverse events reported compared to previous clinical trials with SLIT-tablets. 

Henrik Jacobi, ALK’s Executive Vice President, Research and Development, says: "We are extremely pleased to see such a clear and clinically meaningful treatment effect of the tree allergy immunotherapy tablet. In fact, the clinical effect seen in this trial was among the most significant that we have ever seen in field studies of allergy immunotherapy, which means that we have developed a unique compound.” 

He continues: “With SLIT-tablets for house dust mite, grass, ragweed and Japanese cedar allergies already filed or marketed, these trial results represent an important step forward for ALK in completing its tablet portfolio. With these five tablets, we will be able to effectively cover more than 80% of global respiratory allergies." 

ALK initiated the Phase III clinical trial in 2016 to evaluate the efficacy and safety of the tree SLIT-tablet compared with placebo in adult and adolescent patients with birch pollen allergic rhinitis and/or conjunctivitis. The trial was a randomised, placebo-controlled, double-blind, multi-centre trial involving 634 patients aged 12-65 years in eight European countries. A preceding Phase II trial in an environmental exposure chamber showed that the tablet significantly reduced patients’ symptoms in response to both birch and oak pollen compared with placebo. 

Allergic rhinitis (with or without conjunctivitis) represents a global health problem affecting 10 to 25% of the population. The prevalence in the general population in Europe and North America is ~20%. In Northern and Central Europe, USA and Canada, respiratory allergies are commonly caused by allergens from the birch homologous group of trees, which also includes alder, beech, hazel and oak. ALK estimates that around 15 million Europeans have tree allergies of which ~10% are believed to have symptoms that are not well controlled by conventional symptom-relieving medications. For some of these people with uncontrolled allergies to tree pollen, ALK’s tablet may become a relevant treatment option.    

ALK expects to submit a European and possibly also a Canadian registration application for the tree SLIT-tablet in 2018.

 

ALK-Abelló A/S

 

For further information please contact:

Henrik Jacobi, Executive Vice President, Research and Development, tel. +45 4574 7576

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014

 

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Vedhæftet fil: FM_24_17UK_14092017.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Danske: Moody's ser risiko for sænkning af kreditvurderingen - NY

21-09-2018 15:14:23
Moody's Investors Service er gået i gang med at kigge kreditvurderingen af Danske Bank efter i sømmene og forudser, at der er risiko for en nedjustering. Det oplyser ratinginstituttet fredag, hvor udsigten for Danske Banks kreditvurdering er sænket til "negativ" fra "stabil".Ændringen kommer, efter at banken har offentliggjort rapporten om hvidvask i sin estiske filial tidligere på ugen, skriver M..

Mærsk/Sydbank: Fundamentaler peger ikke mod gode fragtrater

21-09-2018 11:08:55
Efter en periode med overvejende positiv udvikling i fragtraterne er rateindekset Shanghai Containerized Fright Index, SCFI, nu faldet tre uger i træk. Den negative udvikling stopper dog ikke nødvendigvis her, vurderer senioranalytiker Morten Imsgard fra Sydbank, der dækker A.P. Møller-Mærsk. - Nu har vi set tre uger i træk, så det er lidt en trend, men ellers er der stor udsving i de her ugentlig..

Aktier/tendens: Danske Bank trækker overskrifter i ventet grønt marked

21-09-2018 08:04:56
Danske Bank kan fredag komme under investorernes kritiske lup, efter at flere danske aviser endnu engang har banken og undersøgelsen af dens rolle i hvidvasksagen som forsidestof.Børsen kan berette, at selskabet Deminor, der er ekspert i gruppesøgsmål, vil forsøge at samle opbakning blandt aktionærerne til en ny granskning af hvidvasksagen. I Jyllands-Posten Erhverv mener flere eksperter, at det e..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Hold på hat og briller: Wall Street kan blive ramt af udsving fredag
2
Vestas-kunde dropper vindmølleprojekt på 600 megawatt
3
NKT/Jyske: Milliardprojekt nærmer sig - kursmålet løftes - NY
4
Vestas/Sydbank: Venter stærk kvartalsafslutning på ordrefronten
5
Fredagens aktier: Grønt firkløver trak C25 op trods fald i Danske Bank

Relaterede aktiekurser

ALK-Abelló B A/S 1.130,00 1,1% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Berlingske Media 2018  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. september 2018 09:10:52
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180919.1 - EUROWEB4 - 2018-09-22 09:10:52 - 2018-09-22 09:10:52 - 1 - Website: OKAY